Pharmaceuticals 2013, 6(12), 1475-1506; doi:10.3390/ph6121475
Review

Glioblastoma Multiforme Therapy and Mechanisms of Resistance

1 Department of Biochemistry and Molecular Pharmacology and Department of Cancer Biology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA 2 School of Pharmacy, University of Bradford, Bradford BD7 1DP, UK These authors contributed equally to works.
* Author to whom correspondence should be addressed.
Received: 11 September 2013; in revised form: 4 November 2013 / Accepted: 12 November 2013 / Published: 25 November 2013
(This article belongs to the Special Issue Chemotherapeutic Agents)
PDF Full-text Download PDF Full-Text [315 KB, Updated Version, uploaded 26 November 2013 17:44 CET]
The original version is still available [571 KB, uploaded 25 November 2013 16:12 CET]
Abstract: Glioblastoma multiforme (GBM) is a grade IV brain tumor characterized by a heterogeneous population of cells that are highly infiltrative, angiogenic and resistant to chemotherapy. The current standard of care, comprised of surgical resection followed by radiation and the chemotherapeutic agent temozolomide, only provides patients with a 12–14 month survival period post-diagnosis. Long-term survival for GBM patients remains uncommon as cells with intrinsic or acquired resistance to treatment repopulate the tumor. In this review we will describe the mechanisms of resistance, and how they may be overcome to improve the survival of GBM patients by implementing novel chemotherapy drugs, new drug combinations and new approaches relating to DNA damage, angiogenesis and autophagy.
Keywords: angiogenesis; autophagy; imidazotetrazine; MGMT; DNA repair; temozolomide; cancer stem cells

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Ramirez, Y.P.; Weatherbee, J.L.; Wheelhouse, R.T.; Ross, A.H. Glioblastoma Multiforme Therapy and Mechanisms of Resistance. Pharmaceuticals 2013, 6, 1475-1506.

AMA Style

Ramirez YP, Weatherbee JL, Wheelhouse RT, Ross AH. Glioblastoma Multiforme Therapy and Mechanisms of Resistance. Pharmaceuticals. 2013; 6(12):1475-1506.

Chicago/Turabian Style

Ramirez, Yulian P.; Weatherbee, Jessica L.; Wheelhouse, Richard T.; Ross, Alonzo H. 2013. "Glioblastoma Multiforme Therapy and Mechanisms of Resistance." Pharmaceuticals 6, no. 12: 1475-1506.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert